Journal
DNA AND CELL BIOLOGY
Volume 37, Issue 2, Pages 63-69Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/dna.2017.4033
Keywords
kinase inhibitors; antiviral drugs; repurposing; broad-spectrum antivirals
Funding
- NIH [1U19 AI10966201]
- DoD/CDMRP (PRMRP) [PR151090]
- American Cancer Society [RSG-14-11 0-01-MPC]
- Stanford Bio-X
- Stanford SPARK program
Ask authors/readers for more resources
The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach. This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
